ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP21-19 Reminder: Blue Cross Vision Plans with the Davis Vision Network
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 27, 2019
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2811 - 2820 လၢ 3679 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2019 March Provider Press
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP8-19 Addition of Drugs to the Oral Tetracycline Derivatives Prior Authorization Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP12-19 Pharmacy Benefit Update - New Drug-Related Prior Authorization Criteria: Immune Globulins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP15-19 Online Medical Policy Surveys for Authorizations
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP9-19 Addition of Drugs to existing Prior Authorization with Quantity Limit Programs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P17-19 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Medicare Advantage Lines of Business - Effective April 8, 2019
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 30, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P18-19 New Requirements for Non-Emergent Air Ambulance Transport for FEP Standard and Basic Option & FEP Blue Focus Lines of Business - Effective April 8, 2019
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 30, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP22-19 Pharmacy Benefit Update - New Drug-Related Step Therapy Criteria: Methotrexate Injectable
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP18-19 Pharmacy Benefit Update - New Drug-Related Prior Authorization with Quantity Limit Criteria: Sucralfate Suspension
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 27, 2019